首页|基于UHPLC-MS技术的NSCLC血浆生物学标志物的筛选及鉴定研究

基于UHPLC-MS技术的NSCLC血浆生物学标志物的筛选及鉴定研究

扫码查看
目的 研究UHPLC-MS技术的NSCLC血浆生物学标志物的筛选及鉴定.方法 本研究纳入符合非小细胞肺癌临床诊断标准的60例NSCLC患者,随机分为两组,接受靶向治疗(TACE)的非小细胞肺癌患者为鉴别诊断组,未接受靶向治疗的NSCLC患者为正常对照组.结果 在60例NSCLC患者中,通过LC-MS/MS技术共检测到552个生物标志物.在其中17个生物标志物中,有8个出现在已知的EGFR突变患者中,另7个出现在ALK融合患者中,6个出现在HER2突变患者中.此外,NSCLC患者血浆中含有丰富的非编码RNA(miRNA),包括58个miRNA和23个mRNA.结论 本研究中,采用LC-MS/MS技术对NSCLC患者血浆进行分析,可快速、高效地获得血浆样品中的生物学标志物.这些标志物可以作为 NSCLC诊断的潜在生物学标志物,并且可以用于预测肿瘤进展和不良预后.
Screening and Identification Research of NSCLC Plasma Biomarkers Based on UHPLC-MS Technology
Objective To study screening and identification of NSCLC plasma biomarkers with UHPLC-MS technology.Methods The paper chose 60 NSCLC patients met clinical diagnostic criteria for non-small cell lung cancer,and divided them into two groups randomly.Differential diagnosis group with non-small cell lung cancer patients was treated with targeted therapy(TACE),and normal control group with NSCLC patients with no targeted therapy.Results Among 60 NSCLC patients,552 biomarkers were detected with LC-MS/MS technology.Among the 17 biomarkers,8 appeared in known EGFR mutation patients,7 appeared in ALK fusion patients,and 6 appeared in HER2 mutation patients.Moreover,NSCLC patients had abundant non coding RNA(miRNA)in plasma,including 58 miRNAs and 23 mRNA.Conclusion The study analyzes plasma of NSCLC patients with LC-MS/MS technology,which can obtain biological markers in plasma samples quickly and efficiently.The biomarkers can serve as potential biological markers for diagnosis of NSCLC and can be used to predict tumor progression and poor prognosis.

UHPLC-MS technologyNSCPlasma Biomarkers

尹迎秋、彭峰、谢俊玲、尹灵芝、张善强

展开 >

粤北人民医院 呼吸与危重症医学科,广东 韶关 512026

汕头大学医学院 解剖学教研室,广东 汕头 515041

UHPLC-MS技术 NSCLC 血浆生物学标志物

韶关市科技计划(2021)韶关市卫生健康科研项目(2021)

210803154532880Y21070

2024

智慧健康

智慧健康

ISSN:
年,卷(期):2024.10(8)
  • 6